Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMA SAMARO : revenue, balance sheet and financial ratios

PHARMA SAMARO is a French company founded 6 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in LE MANS (72000), this company of category PME shows in 2025 a net income positive of 45 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMA SAMARO (SIREN 854068277)
Indicator 2025 2024 2023 2022 2021 2020
Revenue N/C N/C N/C N/C N/C N/C
Net income 44 574 € 45 373 € 45 362 € 45 131 € 45 084 € -33 287 €
EBITDA -4 469 € -3 570 € -3 456 € -3 561 € -3 502 € -31 900 €
Net margin N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, PHARMA SAMARO generates positive net income of 45 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-4 469 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-4 469 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

44 574 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 131%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 6.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

131.2%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

43.253%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

6.832

Solvency indicators evolution
PHARMA SAMARO

Sector positioning

Debt ratio
131.2 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average

In 2025, the debt ratio of PHARMA SAMARO (131.20) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
43.25% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Average +11 pts over 3 years

In 2025, the financial autonomy of PHARMA SAMARO (43.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
6.83 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.77 years
Q3: 6.12 years
Average

In 2025, the repayment capacity of PHARMA SAMARO (6.83) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-19.915

Liquidity indicators evolution
PHARMA SAMARO

Sector positioning

Interest coverage
-19.91x 2025
2023
2024
2025
Q1: -191.54x
Med: -25.42x
Q3: 0.0x
Good +12 pts over 3 years

In 2025, the interest coverage of PHARMA SAMARO (-19.9x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Positioning of PHARMA SAMARO in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of PHARMA SAMARO is estimated at 462 089 € (range 286 428€ - 718 695€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
286k€ 462k€ 718k€
462 089 € Range: 286 428€ - 718 695€
NAF 5 all-time

Valuation method used

Net Income Multiple
44 574 € × 10.4x = 462 090 €
Range: 286 428€ - 718 695€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare PHARMA SAMARO with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about PHARMA SAMARO

What is the revenue of PHARMA SAMARO ?

The revenue of PHARMA SAMARO is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMA SAMARO profitable?

Yes, PHARMA SAMARO generated a net profit of 45 k€ in 2025.

Where is the headquarters of PHARMA SAMARO ?

The headquarters of PHARMA SAMARO is located in LE MANS (72000), in the department Sarthe.

Where to find the tax return of PHARMA SAMARO ?

The tax return of PHARMA SAMARO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMA SAMARO operate?

PHARMA SAMARO operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.